Investor presentation, 27 May 2024
Released
Released
Announcement PDF
NNZ-2591 Pitt Hopkins
syndrome Phase 2 trial
top-line results
27 May 2024
IMPROVING THE LIVES OF PEOPLE WITH
NEURODEVELOPMENTAL DISABILITIES
Page□
1
Forward looking statements
This presentation contains forward looking statements that involve
risks and uncertainties. Although we believe that the expectations
reflected in the forward looking statements are reasonable at this
time, Neuren can give no assurance that these expectations will
prove to be correct. Actual results could differ materially from those
anticipated. Reasons may include risks associated with drug
development and manufacture, risks inherent in the regulatory
processes, delays in clinical trials, risks associated with patent
protection, future capital needs or other general risks or factors.
2
Pitt Hopkins syndrome has overwhelming unmet medical need
Cause of the syndrome
Deletion or variation in the
TCF4 gene on chromosome
18
TCF4 protein plays a role in
the formation, maintenance
and function of dendrites
and synapses
Broad and severe impact on life
Patients stories
Intellectual impairment
Behavioural issues
Sensory processing disorder
Sleep disorders
Seizures
Vision impairment (severe myopia)
Language deficits
Breathing problems (hyperventilation,
apnea, breath-holding)
Feeding difficulties
Pitt Hopkins Research Foundation
Motor impairments including
hypotonia (low muscle tone) and
gross and fine motor delays
GI dysfunction (gastroesophageal
reflux and constipation)
Walking abnormalities
“She was tested earlier for Angelman and Rett
Syndrome, but they were of course negative. I had
a strange feeling that something was wrong with
her already when she was a newborn…I started to
see different doctors with her, but they just told me
nothing was wrong, until we met a Neurologist who
told us that she had Cerebral Palsy and that she
would not able to walk, ever…She doesn’t talk but
when she was about one year old she was saying
a few words that never ever came back...”
“Caleb is currently 10 months old and he does not
sit or roll yet and is not really interested in toys. He
is currently in an early intervention program and is
going through physical therapy, and sees a vision
teacher and special education teacher…It has not
been an easy journey thus far. I still do not how
and where I get all my strength from. I know things
will only get harder as he gets older but I am ready
to accept the challenge and take each day as it
comes.”
3
Consistent efficacy observed for NNZ-2591 in TCF4 mouse model
Hypoactivity
Daily living
Learning & Memory
Sociability
Repetitive behavior
Motor performance
4
Phase 2 clinical trial results highlights
•
NNZ-2591 was safe and well tolerated, with no meaningful trends in laboratory values or other
safety parameters during treatment
•
Statistically significant improvement from baseline assessed by both clinicians and caregivers
in all 4 efficacy measures specifically designed for Pitt Hopkins syndrome (p<0.05) 1
•
Clinician and caregiver global efficacy measures showed a level of improvement considered
clinically meaningful:
•
•
PTHS Clinical Global Impression of Improvement (CGI-I) – mean score of 2.6 with 9 out of 11 children
showing improvement assessed by clinicians
•
PTHS Caregiver Overall Impression of Change (CIC) – mean score of 3.0 with 8 out of 11 children
showing improvement assessed by caregivers
Improvements were seen in clinically important aspects of Pitt Hopkins syndrome, including
communication, social interaction, cognition and motor abilities
1 Wilcoxon signed rank test
5
Phase 2 Clinical
Trial Design
6
Neuren’s Phase 2 trial in children with Pitt Hopkins syndrome
First study in pediatric patients, collecting the data needed to design a registration study
5 US sites: Rush University,
UTSW, UCSF, UAB, Colorado
Children’s Hospital
NNZ-2591 treatment
Screening
/Baseline
Up-titration to
12 mg/kg BID
16 subjects, age 3-17
Week 4
Week 0
•
•
•
PTHS specific efficacy measurements
Primary endpoints were
safety, tolerability and PK
Global
A key objective is selection of
the best primary efficacy
endpoint or endpoints for a
registration study
Week 17
Week 10
Endpoints
Secondary endpoints included
14 efficacy measurements,
including 4 specifically
designed for PTHS
Follow-up
•
CGI-I
•
Caregiver Impression of Change (CIC)
•
CGI-S
+
Week 19
10 other non PTHS
specific measures
that had been used
in other conditions
Symptom Specific
•
Caregiver Top 3 Concerns
7
Participant Disposition
16 enrolled
15
1 discontinued due to
inability to complete safety
monitoring procedures
11 completers
4 discontinued
due to TEAE
•
Discontinuations due to TEAEs, all
mild/moderate, all resolved:
•
2 due to TEAEs unrelated to drug (COVID19 and mild vomiting, diarrhea, lethargy)
•
1 due to moderate constipation, self injury,
abdominal distention, fatigue
•
1 due to mild sleep disorder, constipation
8
Participant demographics
Low IQ/DQ reflecting severity of the syndrome
Sex
Age
Cognitive level
(non-verbal IQ/DQ)
CGI-S
(at Baseline)
>=35,
n=1, 6%
Mean
9.1yrs
Median
9.5yrs
Female,
8, 50%
Mean (SD)
5.0 (0.69)
3-12yrs: N = 11
13-17yrs: N = 5
Male, 8,
50%
<35,
n=15,
94%
Completers average DQ: 12
9
Safety and
Tolerability
10
Safety and tolerability summary
NNZ-2591 was safe and well tolerated
✓ Well tolerated
TEAEs in 2 or more subjects
✓ All Treatment Emergent
Adverse Events (TEAE)
were mild to moderate,
mostly not drug related
Event
•
0 Serious TEAE
•
4 discontinuations due
to TEAEs, all
mild/moderate, all
resolved
✓ No meaningful trends in
laboratory values,
electrocardiogram (ECG) or
other safety parameters
were observed during
treatment
N=16
n (%)
Event
N=16
n (%)
Constipation
3 (19)
2 mild, 1 mod
Contusion
2 (13)
all mild
Diarrhea
4 (25)
all mild
Gastroenteritis-viral
2 (13)
1 mild, 1 mod
Vomiting
2 (13)
all mild
Nasopharyngitis
3 (19)
all mild
Fatigue
4 (25)
3 mild, 1 mod
Cough
2 (13)
all mild
Somnolence
2 (13)
all mild
Rhinorrhea
2 (13)
all mild
Irritability
2 (13)
all mild
Decreased appetite
2 (13)
all mild
11
Efficacy
12
Efficacy endpoints summary
•
•
•
CGI-I 2.6
Mean
of
and Median of 3.0 with
p-value = 0.0039
Efficacy measures and p-values1 (Total/Overall scores)
PTHS Specific Endpoints
Completers (MITT)
N=11
Including
discontinued
N=15
CGI-I
0.0039
0.0205
CIC
0.0234
0.0137
CGI-S
0.0313
0.0078
Caregiver Top 3 Concerns
0.0077
0.0024
CIC 3.0
Mean
of
and Median of 3.0 with
p-value =0.0234
Statistically significant
improvement vs baseline in
4/4 PTHS
specific
endpoints
•
Changes from baseline for the measures that were not designed for PTHS
were not statistically significant
1 Wilcoxon signed rank test
13
Best practice implemented for PTHS-specific CGI-I and CIC measures
•
Both CGI-I and CIC scores
reflect overall improvement
from baseline
1 – Very Much Improved
Clinical Global Impression of
Improvement (CGI-I)
Scoring
Clinician gives an overall score Caregiver gives an overall
and scores each domain
score and scores each domain
Also identifies the one symptom
area that has most influenced
his or her rating of the child’s
overall function
Domain
Anchors
•
Language/Communication
•
Communication
•
Social Interaction
•
Social interaction
•
Ambulation/Gross Motor
•
Motor abilities
•
Fine Motor/Self-Help
•
Self-care skills
•
GI Issues
•
GI Problems
•
Autonomic/Breathing
Abnormalities
•
Breathing Problems
•
Behavior
•
Seizures
•
Cognitive abilities/ability to
learn
2 – Much Improved
3 – Minimally Improved
4 – No Change
5 – Minimally Worse
6 – Much Worse
7 – Very Much Worse
•
•
All clinician raters completed
training to calibrate scoring and
interpretation of the scoring
anchors amongst raters
Training was done at study
start up and a follow-up
calibration training was done
during the study
Caregiver Impression of
Change (CIC)
•
Challenging Behaviors
14
PTHS CGI-I (clinician) results by subject and by domain
Mean CGI-I score of 2.6 with 9 out of 11 children showing improvement
CGI-I Overall Score by subject
Forest Plot of mean CGI-I Domain Scores
MITT Population
MITT Population
Subject
Improvement
15
PTHS CIC (caregiver) results by subject and by domain
Mean CIC score of 3.0 with 8 out of 11 children showing improvement
CIC Overall Score by subject
Forest Plot of mean CIC Domain Scores
MITT Population
MITT Population
Subject
Improvement
16
PTHS Clinical Global Impression of Severity (CGI-S) and Caregiver Top 3
Concerns results by domain
6 subjects improved by one point on the overall CGI-S score after 13 weeks of treatment and
improvement was observed in the most common concerns of caregivers (communication, self
care, behaviour, motor skills)
Caregiver Top 3 Concerns
CGI-S Scores
(Domains and frequency of nomination)
MITT Population
7
Forest Plot of Mean Change from Baseline in Top 3 Concerns Domain
Severity
Improvement
Improvement
MITT Population
6
Social Interest/Avoidance (n=1)
5
Self Care (n=7)
4
Fine Motor Skills (n=3)
3
Language/Communication (n=11)
Gross Motor Skills (n=4)
2
Gastrointestinal Problems (n=2)
1
Challenging Behaviour (n=4)
0
Baseline
End of Treatment
Improvement
17
Testimonials
18
Clinician and caregiver testimonials
Clinicians
“Increased babbling and jargoning….More inflections with
eye contact and consonant sounds rather than just noises.”
Caregivers
“Is now able to explore environment… can move towards
people to initiate contact and… can seek out whatever …
wants to play with.”
“Decreased frequency and intensity of smacking and
hairpulling.”
“Can seem to hold on to things for longer periods without
letting go.”
“Supported stepping increased over last few months…Now
taking steps without trainer with parent support.”
“Stability when walking improved.”
“Improved expressive communication: 2 additional words,
uses AAC device to ask for food. Increase vocalization.”
“Less breath holding. More opinionated. More social
interest.”
“Able to match items/pictures…moved from 4 pictures to 6
pictures.”
“Improved motor skills. Better motor coordination getting in
car.”
“Listen to conversation + follow some discussions, able to
understand when we’re talking about…”
“Far less hyper and easily able to concentrate better… is
able to concentrate and master tasks that … has been
working on for years (getting in and out of car
independently, catching a ball).”
“More intentional movements… been more gentle with
almost all interactions.”
“Almost constant babbling and even has said “hi” and
“more.””
“More calm and attentive, especially looking at faces and
eyes.”
19
PTHS
opportunity
20
PTHS is historically under-diagnosed, but this is changing
Estimated prevalence is 1/34,000 to 1/41,000 males and females1
Potential PTHS patients
US
Europe
Japan
China
Other2
6,000 – 7,0003
8,000 – 9,0003
1,000 - 2,0003
18,000 – 22,0003
6,000 - 7,0003
Pitt Hopkins Syndrome Census –
initiated Q1 20231
1,391
1,318
1,237
1,188
1,083
Currently
497 in US
& Canada,
329 in EMA
& UK, 248
in China,
60 in ANZ
Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024
Opportunity to accelerate diagnosis
Clinical similarities
between PTHS,
Rett and Angelman
syndromes calling
for TCF4 screening
in suspected Rett
or Angelman
patients4
•
Rising awareness
•
ICD code assigned in
2020
•
Enhanced genetic
testing technologies
•
Expanding ADDM
network sites
Autism
US ADDM tracks
440k children with
autism spectrum
disorder
1 Pitt Hopkins Research Foundation (PHRF) (pitthopkins.org)
2 Brazil, Israel, South Korea, Australia and New Zealand
3 Estimates based on United Nations population data 2022, derived by applying the estimated prevalence range to the populations under 60 years (urban population only for China)
4 Takano et al, “Two percent of patients suspected of having Angelman syndrome have TCF4 mutations” Clin Genet. 2010 Sep;78(3):282-8; Armani et al, “Transcription factor 4 and myocyte enhancer factor 2C
mutations are not common causes of Rett syndrome” Am J Med Genet A. 2012;158A(4):713–9
21
Neuren is leading development of a first approved treatment for PTHS
Neuren Program Status
•
Positive Phase 2 trial
•
Clinical development in the
US under an IND
Limited products in development
Company
Neuren engaging with all
stakeholders
Product Development Stage
•
Orphan Drug designation in
US and EU
Successful Phase 2
•
Eligible for Rare Pediatric
Disease Designation
Priority Review Voucher
program
#2
Phase 2 (research institute
sponsored, focusing on GI
symptoms)
#3
Phase 1/2a trial (not yet
recruiting)
#4
Preclinical
Leading clinicians
22
NNZ-2591 as
multi-indication
platform
23
Regulating IGF-1 in the brain
Reversible binding
regulates
bioavailability
IGF-1
Produce
essential
growth factor
Activates PI3K-AktmTOR and Ras-MAPKERK signaling pathways
in neurons, regulating
formation of new
synapses
1 doi: 10.1038/srep04388: Guan et al, 2017: Cyclic glycine-proline (cGP) regulates
IGF-1
receptor
on cell
surface
•
NNZ-2591 is a synthetic analog
of cyclic glycine proline, a
peptide that occurs naturally in
the brain, designed to be more
stable, orally bioavailable and
readily cross the blood-brain
barrier
•
NNZ-2591 can regulate the
amount of IGF-1 that is
available to activate IGF-1
receptors
•
The effects of NNZ-2591 are
“state-dependent” – correcting
impairment, but not impacting
normal cells
IGF
Binding
Protein‐3
Competitively binds to
binding protein,
regulating IGF-1
binding1
NNZ-2591
IGF-1 homeostasis by altering the binding of IGFBP-3 to IGF-1
24
Phase 2 trial results validating multi-indication platform
Phelan-McDermid syndrome
N=18, 13 weeks
General safety &
tolerability
Serious TEAEs
Pitt Hopkins syndrome
N=11, 13 weeks
Safe and well tolerated, with no meaningful Safe and well tolerated, with no meaningful
trends in laboratory values or other safety trends in laboratory values or other safety
parameters during treatment
parameters during treatment
1 unrelated to drug
0
Mean CGI-I
2.4 (89% shown improvement)
2.6 (82% shown improvement)
Mean CIC
2.7 (83% shown improvement)
3.0 (73% shown improvement)
# patients had CGI-S
improvement of 1
7 (39%)
6 (55%)
# syndrome-specific
efficacy measures
statistically significant1
5/5
4/4
1 Wilcoxon signed rank test
25
Good safety profile supports review of trial protocol for future indications
•
Positive data from Phelan McDermid syndrome and Pitt Hopkins syndrome Phase 2 trials support review and
potential optimisation of existing Phase 2 trial protocol for Prader-Willi syndrome and future indications, subject to
FDA agreement
•
To reduce excessive burden on patients and their families
•
To enhance competitiveness vs ongoing Prader-Willi syndrome trials in the US
•
To expedite future development in other indications
•
Prader-Willi syndrome Phase 2 trial has been paused, pending review of the trial protocol post planned End of Phase
2 Meeting with the FDA in Q3 2024 for Phelan-McDermid syndrome
•
Pre-clinical studies are ongoing for other indications that could potentially move into Phase 2 with an optimised
protocol
26
Multiple indications opportunity for NNZ-2591
Pitt Hopkins
syndrome
NNZ-2591
PhelanMcDermid
syndrome
Angelman
syndrome
(Q3 2024)
•
Prader-Willi
syndrome
Positive results from Phelan
McDermid syndrome and Pitt
Hopkins syndrome Phase 2 trials
•
Other
undisclosed
indications
Top-line results from Angelman
syndrome Phase 2 trial expected in
Q3 2024
•
Rett
syndrome
(Acadia)
End of Phase 2 meeting with FDA
for Phelan McDermid syndrome
planned Q3 2024
•
The mechanism of action of NNZ-2591
is relevant for many other
neurodevelopmental synaptopathies
•
Rett and Fragile X syndromes are
licensed to Acadia, with same
economics to Neuren as trofinetide;
Neuren retains worldwide rights to all
other indications
Fragile X
syndrome
(Acadia)
27
CONTACT
Jon Pilcher, CEO
jpilcher@neurenpharma.com
+61 438 422 271
28
Share your feedback
Discover